Unicycive Therapeutics, Inc.

UNCY

US90466Y1038

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:13:10 2024-07-10 pm EDT			5-day change	1st Jan Change
0.492 ^USD	+3.34%		0.00%	-43.53%

01:03pm	Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate	CI
Jul. 05	Unicycive Therapeutics Files Shelf Registration for Sale of Up to 50 Million Shares by Stockholders	MT

Unicycive Therapeutics, Inc.(NasdaqCM:UNCY) added to Russell Microcap Index

July 30, 2024

Latest news about Unicycive Therapeutics, Inc.

Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate	07:03am	CI
Unicycive Therapeutics Files Shelf Registration for Sale of Up to 50 Million Shares by Stockholders	Jul. 05	MT
Unicycive Therapeutics, Inc.(NasdaqCM:UNCY) added to Russell Microcap Growth Index	Jun. 30	CI
Unicycive Therapeutics, Inc.(NasdaqCM:UNCY) added to Russell 3000E Index	Jun. 30	CI
Unicycive Therapeutics, Inc.(NasdaqCM:UNCY) added to Russell Microcap Index	Jun. 30	CI
Unicycive Therapeutics, Inc.(NasdaqCM:UNCY) added to Russell 3000E Growth Index	Jun. 30	CI
Unicycive Therapeutics, Inc.(NasdaqCM:UNCY) added to Russell Microcap Value Index	Jun. 30	CI
Unicycive Therapeutics, Inc.(NasdaqCM:UNCY) added to Russell 3000E Value Index	Jun. 30	CI
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate Pivotal Clinical Trial	Jun. 25	CI
Unicycive Therapeutics, Inc. Delivers Multiple Presentations on Oxylanthanum Carbonate and Uni-494 At the European Renal Association Congress	May. 28	CI
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate At the National Kidney Foundation Spring Clinical Meeting	May. 15	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Piper Sandler Initiates Coverage on Unicycive Therapeutics With Overweight Rating, $9 Price Target	Apr. 04	MT
Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Unicycive Therapeutics, Inc. announced that it has received $50 million in funding	Mar. 19	CI
Unicycive Therapeutics, Inc. announced that it expects to receive $50 million in funding	Mar. 13	CI
Unicycive Therapeutics Completes Patient Enrollment in Pivotal Trial for Investigational Therapy for Hyperphosphatemia	Mar. 08	MT
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate	Mar. 07	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Unicycive Therapeutics Reaches Alignment with the Fda on Path to File New Drug Application for Oxylanthanum Carbonate	23-10-23	CI
Unicycive Therapeutics, Inc. Announces Appointment of Sara Kenkare-Mitra to Board of Directors	23-09-06	CI
HC Wainwright Adjusts Unicycive Therapeutics' Price Target to $4.50 From $7, Keeps Buy Rating	23-08-16	MT
Unicycive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Unicycive Therapeutics Files Registration Statement on Behalf of Selling Stockholders	23-07-13	MT
Maxim Adjusts Price Target on Unicycive Therapeutics to $4 From $6, Maintains Buy Rating	23-07-03	MT

Chart Unicycive Therapeutics, Inc.

Duration

Period

More charts

Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.4761 USD

Average target price

5.75 USD

Spread / Average Target

+1,107.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
UNICYCIVE THERAPEUTICS, INC.	-43.53%	17.9M
MODERNA, INC.	+19.89%	44.48B
LONZA GROUP AG	+44.19%	40.57B
IQVIA HOLDINGS INC.	-8.55%	38.82B
ALNYLAM PHARMACEUTICALS, INC.	+33.67%	32.22B
CELLTRION, INC.	-8.34%	27.84B
ICON PUBLIC LIMITED COMPANY	+15.57%	26.79B
UNITED THERAPEUTICS CORPORATION	+49.18%	14.31B
MEDPACE HOLDINGS, INC.	+36.12%	12.7B
BIO-TECHNE CORPORATION	-7.02%	11.23B

Other Biotechnology & Medical Research